From infectious disease to oncology: translating a novel glycan target into a ‘pan-cancer’ ADC
Year: 2026
Type: article
Abstract: “We recently obtained the first data ... which demonstrates that the antibody reaches the tumors to a significant extent with very limited off-target binding.”Lauren Coyle, Editor, Bioconjugate Insights, speaks with Ali Salanti, Professor, University of Copenhagen, and CEO, Var2 Pharma, about the development of a new monovalent ADC with broad anti-tumor activity – from a serendipitous discovery to preparing for clinical trials.
Source: Bioconjugation Insights
Author: Ali Salanti
Institution: University of Copenhagen
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7140174375
FWCI:
Cites:
Cited by:
Related to: